Mast cells – a new view of the old acquaintances

1. Ehrlich P. Beiträge zur Theorie und Praxis der histologischen Färbung. Thesis, Liepzig University 1878.

2. Hakim-Rad K, et al. Mast cells: makers and breakers of allergic inflammation. Curr Opin Allergy Clin Immunol 2009; 9: 427–430.

3. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112: 946–956.

4. Schulman ES, et al. Heterogeneity of human mast cells. J Immunol 1983; 131: 1936–1941.

5. Tabares L, et al. Relationship between fusion pore opening and release during mast cell exocytosis studied with patch amperometry. Biochem Soc Trans 2003; 31: 837–841.

6. Irani AA, et al. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83: 4464–4468.

7. Krishnaswamy G, et al. The human mast cell: an overview. Methods Mol Biol 2006; 315: 13–34.

8. Janicki JS, et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 2006; 69: 657–665.

9. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 1997; 61: 233–245.

10. Stenton GR, et al. Role of intestinal mast cells in modulating gastrointestinal pathophysiology. Ann Allergy Asthma Immunol 1998; 81: 1–11.

11. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008; 49: 7–19.

12. Gordon JR, Galli SJ. Release of both preformed and newly synthesized tumor necrosis factor-α (TNF-α)/cachectin by mouse mast cells stimulated via the FcεRI. A mechanism for the sustained action of mast cell-derived TNF-α. during IgE-dependent biological responses. J Exp Med 1991; 174: 103–107.

13. Taildeman J, et al. Human mast cells express leptin and leptin receptors. Histochem Cell Biol 2009; 131: 703–711.

14. Rudolph MI, et al. Uterine mast cells: a new hypothesis to understand how we are born. Biocell 2004; 28: 1–11.

15. Bosquiazzo VL, et al. Mast cell degranulation in rat uterine cervix during pregnancy correlates with expression of vascular endothelial growth factor mRNA and angiogenesis. Reproduction 2007; 133: 1045–1055.

16. Varayoud J, et al. Mast cells degranulation affects angiogenesis in the rat uterine cervix during pregnancy. Reproduction 2004; 127: 379–387.

17. Bytautiene E, et al. The effect of a mast cell degranulating agent on vascular resistance in the human placental vascular bed and on the tone of isolated placental vessels. Reprod Sci 2008; 15: 26–32.

18. Yokoi H, et al. High incidence of uterine inversion in mast cell-deficient osteopetrotic mutant mice of mi/mi genotype. Biol Reprod 1994; 50: 1034–1039.

19. Schmidt A, et al. Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-alpha activated human vascular endothelial cells. Atherosclerosis 2002; 164: 57–64.

20. Osman I, et al. Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term. Mol Hum Reprod 2003; 9: 41–45.

21. Huang J, et al. Cellular localization and hormonal regulation of inducible nitric oxide synthase in cycling mouse uterus. J Leukoc Biol 1995; 57: 27–35.

22. Swindle EJ, Metcalfe DD. The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev 2007; 217: 186–205.

23. Konopka TE, et al. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001; 61: 3182–3187.

24. Milne SA, et al. Co-localization of matrix metalloproteinase-1 and mast cell tryptase in the human uterus. Mol Hum Reprod 2001; 7: 559–565.

25. Vasiadi M, et al. Progesterone inhibits mast cell secretion. Int J Immunopathol Pharmacol 2006; 19: 787–794.

26. Hattori Y, et al. Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma. Exp Mol Pathol 2003; 74: 230–237.

27. Vega E, Rudolph MI. Characterization of oxytocin receptors and serotonin transporters in mast cells. Endocrine 2002; 18: 167–172.

28. Kempuraj D, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 2004; 145: 43–48.

29. Norrby K. Mast cells and angiogenesis. Apmis 2002; 110: 355–371.

30. Maltby S, et al. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796: 19–26.

31. Norrby K, et al. Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol 1986; 52: 195–206.

32. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093–1107.

33. Tchougounova E, et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291–9296.

34. Novotná J. Pojivové bílkoviny periferních plicních cév při chronické hypoxii. Čs Fyziol 2009; 2: 49–52.

35. Novotná J, Herget J. Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 2002; 51: 323–334.

36. Herget J, et al. A possible role of oxidant tissue injury in the development of pulmonary hypertension. Physiol Res 2000; 49: 493–501.

37. Novotná J, et al. Hyperoxia and recovery from hypoxia alter collagen in peripheral pulmonary arteries similarly. Physiol Res 2001; 50: 153–163.

38. Vajner L, et al. Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 2006; 87: 383–391.

39. Maxova H, et al. In vitro hypoxia increases production of matrix metalloproteinases and tryptase in isolated rat lung mast cells. Physiol Res 2008; 57: 903–910.

40. Maxová H, et al. Effect of N-acetylcysteine on tissue metalloproteinases activity in RBL-2H3 mast cells exposed to 24 hours of “in vitro” hypoxia. Phys Res 2004; 53: 24P.

41. Lachmanova V, et al. N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci 2005; 77: 175–182.

42. Banasova A, et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008; 76: 102–107.

43. Riley DJ, et al. Role of proteolysis and apoptosis in regression of pulmonary vascular remodeling. Physiol Res 2000; 49: 577–585.

44. Maxová H, et al. Prevention of mast cell degranulation by disodium cromoglycate delayed the regression of hypoxic pulmonary hypertension in rats. Respiration (Published online: April 10, 2010).

45. Hara M, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002; 195: 375–381.

46. Esposito I, et al. Mast cell distribution and activation in chronic pancreatitis. Hum Pathol 2001; 32: 1174–1183.

47. Joseph J, et al. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H2541–2545.

48. Miyazawa S, et al. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int 2004; 65: 2228–2237.

49. Maxová H, et al. Kromoglykát sodný – blokátor degranulace žírných buněk v procesu tkáňové remodelace. Čs Fyziol 2010; 59: 21–23.

50. Gopalan R, Goldberg S. Tranilast in the Therapy of Coronary Artery Disease. Curr Interv Cardiol Rep 2000; 2: 149–156.

51. Shiota N, et al. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 1999; 99: 1084–1090.